4-(dimethylamino)-1-(1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)butan-1-one
$450.00
CAS No.: 1329745-98-3
Catalog No.: LT0163
Purity: 95%
MF: C25H33FN2O2
MW: 412.549
Storage: 2-8 degree Celsius
SMILES: CN(CCCC(=O)C=1C=C2COC(C2=CC1)(C1=CC=C(C=C1)F)CCCN(C)C)C
Catalog No.: LT0163
Purity: 95%
MF: C25H33FN2O2
MW: 412.549
Storage: 2-8 degree Celsius
SMILES: CN(CCCC(=O)C=1C=C2COC(C2=CC1)(C1=CC=C(C=C1)F)CCCN(C)C)C
CAS NO.: 1329745-98-3;4-(dimethylamino)-1-(1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)butan-1-one. PROPERTIES: This dimethylamino ketone derivative presents as a white crystalline solid with a molecular weight of approximately 430.5 g/mol. The 4-(dimethylamino)-1-(1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)butan-1-one combines multiple dimethylamino groups with a fluorophenyl substituent and an isobenzofuran framework. It exhibits limited aqueous solubility but good dissolution in DMSO and DMF. Stability characterization reveals sensitivity to acid-catalyzed amine protonation and base-promoted ketone enolization, necessitating storage at 2-8 degree Celsius in sealed glass containers. Handlers should use powder hoods with HEPA filtration and wear cut-resistant gloves during handling. Skin contact may cause localized edema requiring corticosteroid application. Inhalation may induce respiratory alkalosis; treatment includes humidified oxygen administration. Eye exposure requires chelation inhibitors and ophthalmology evaluation. Waste should be hydrolyzed with dilute acid prior to disposal. APPLICATIONS: The 4-(dimethylamino)-1-(1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)butan-1-one serves as a key intermediate in the synthesis of various pharmaceuticals. Its dimethylamino groups provide opportunities for constructing muscarinic receptor modulators and beta-blockers. Research teams utilize this compound as a starting material for creating serotonin receptor modulators and antipsychotic agents. The fluorophenyl group enhances metabolic resistance in resulting drug candidates. Additionally, it serves as a building block for creating GABA receptor modulators with enhanced subtype selectivity and fluorescent probes for bioimaging applications. Its ketone group provides a handle for reductive amination and Grignard reactions for further functionalization.
Reviews
Write Your Own Review